Pyxis Oncology PYXS announced that it has dosed the first patient in a phase I study of PYX-106, a fully human immunotherapy antibody candidate. The company's shares rose 4.15% on the pipeline ...
Having recently trimmed back its pipeline to a sole cancer candidate, Pyxis Oncology has now reduced its head count to match. The Boston biotech is shrinking its workforce by "approximately" 20%, it ...
BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today ...
Pyxis Oncology (NASDAQ:PYXS) is down ~38% in after-hours trading Wednesday after posting preliminary phase 1 data on PYX-201, an antibody-drug conjugate for solid tumors. The data presented was in six ...
Pyxis Oncology had cash and cash equivalents, including restricted cash and short-term investments of $157.2 million. Pyxis says that its current cash, cash equivalents, and short-term investments ...
Apexigen’s rapid decline is nearly complete. Three years after its private megaround, and less than 300 days after going public, the biotech has accepted a $16 million buyout bid from Pyxis Oncology.
Pyxis Oncology is developing next-generation therapeutics, including antibody-drug conjugates and immuno-oncology programs, to target solid tumors resistant to current treatments. PYXS's lead product ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback